Abstract B003: A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models

Kristin Adams,Ryan Moreno,Jae-Rim Wendt,Josie Wood,Avtar Roopra,Jessica D. Lang

DOI: https://doi.org/10.1158/1538-7445.ovarian23-b003

IF: 11.2

2024-03-05

Cancer Research

Abstract:Despite being rare cancers, ovarian cancer rank as the fifth leading cause of cancer mortalities in women in the United States. Most patients are detected late, with most patients diagnosed in Stages 3 and 4. While patients often initially respond to standard of care chemotherapy, which includes platinum-based chemotherapy such as cisplatin and carboplatin, they recur with resistant phenotypes. While a large effort has characterized mechanisms of resistance to platinum-based chemotherapy, it is still challenging to identify these patients and identify more promising therapies. While the field understands that a quiescent, stem cell-like state can serve as an intermediate from which chemoresistant recurrences can arise, the epigenetics of this state are less well understood. In fact, we do know that embryonic and pluripotent stem cells differ significantly in enhancers and other epigenetic features that contribute significantly to their phenotypes. We performed histone post-translational modifications by CUT&Tag, as well as ATACseq and RNA-seq, on four isogenic cell line models of cisplatin resistance. We show that these models are resistant to both cisplatin and carboplatin. While we see paradoxical quiescent cell markers in these isogenic lines, we have characterized differential features of their epigenetics that may contribute to the resistant phenotype. We are continuing to explore transcription factors that may drive this resistance. We are also examining super-enhancers that are altered between chemo-sensitive and -resistant cell lines. Similarly, we have examined whether inhibitors of components of super-enhancers may be a viable therapeutic option for platinum-resistant high-grade serous ovarian cancer patients. We see moderate synergy between triptolide (targets TFIIH subunit XPB1) and JQ-1 (targets BRD4) with cisplatin in resistant models. Together, we hope our studies can contribute to the knowledge of how epigenetic features might contribute and be targets for chemoresistance in ovarian cancer. Citation Format: Kristin Adams, Ryan Moreno, Jae-Rim Wendt, Josie Wood, Avtar Roopra, Jessica D. Lang. A multi-omic analysis to identify epigenetic drivers of platinum-resistance in high-grade serous ovarian carcinoma models [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2) nr B003.

oncology